NorEpiNet

From genes to treatment: Understanding epilepsy genetics and precision medicine
Oslo, November 24th and 25th, 2025

Day 1: Monday 24th of November

09:30–10:00: Registration, coffee and sandwiches

SESSION 1:	**Basics and background**
10:00–10:15	**Introduction of course and participants**
10:15–10:45	**Why does epileptology need genetics and precision medicine?** Tommy Stödberg, MD, PhD
10:45–11:20	**Genetics: Basics and methods** Kaja Selmer, MD, PhD
11:20–12:00	**Genetic evaluation, diagnosis, and counselling** Inger-Lise Mero, Clinical Geneticist, MD, PhD
12:00–13:00	**Lunch break**
SESSION 2:	**Epilepsy genetics**
13:00–13:45	**State of the art of genetic investigations in epilepsy in 2025** Rikke Steensbjerre Møller, Professor, MSc, PhD
13:45–14:30	**A genotype-phenotype clinical interpretation approach** Elena Gardella, Prof., MD PhD and Rikke Steensbjerre Møller, Prof, MSc PhD
14:30–14:45	**Mini break – leg stretch**
14:45–15:45	***In silico* prediction tools and online portals for variant interpretation** Christian Bosselmann, MD, PhD
15:45–16:15	**Mini break – with snacks**
SESSION 3:	**Workshop and hands on variant evaluation**
16:15–16:45	**Introduction to case workshops on variant evaluation**
16:45–17:45	**Case work in groups**
17:45–18:15	**Round-up in plenum**
18:15–18:30	**Summary of day 1**
1930	**Dinner**

Day 2: Tuesday 25th of November, 2025

SESSION 4:	**Precision treatment**
09:00–09:30	**Patient perspectives**
09:30–10:00	**Somatic mutations in focal cortical dysplasia** Fridny Heimisdottir, Pediatrician, MD
10:00–10:40	**Principles of clinical pharmacology and pharmacogenetics** Cecilie Johannessen Landmark, Professor, MScPharm, PhD
10:40–11:10	**Drug repurposing in epilepsy** Allan Bayat, Ass. Professor, MD, PhD
11:10–11.30	**Break**
11:30–12:30	**Precision medicine – state of the art and future perspectives** Amy McTague, MD, PhD
12:30–13:30	**Lunch break**
SESSION 5:	**Clinical case discussions**
13:30–15:00	**Plenary seminar: Cases from participants**
15:00–16:00	**Clinical discussions, evaluations, conclusions**

Endorsed by: ILAE International League Against Epilepsy; EpiCARE

Funded by: NordForsk